Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7MW3711 in Advanced Solid Tumors
NCT06008379Phase 2Recruiting
- Sponsor
- Mabwell
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of 7MW3711 in solid tumor (advanced stage), sponsored by Mabwell. Started Aug 2023; status: recruiting.
02
Drugs
7MW3711
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06008379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008379.